« Back

GTx, Inc. Initiates 2-Year Internship Program for Area College Students Pursuing Degrees in Science (January 09, 2004)

Jan 9, 2004 at 12:00 AM EST
Contact:
GTx, Inc.
Carney Duntsch
Investor and Media Relations
901-523-9700 ext. 170
cduntsch@gtxinc.com
 

Burns McClellan, Inc.
Jonathan M. Nugent (investors)
Kathy L. Jones-Nugent, Ph.D. (media)
212-213-0006







GTx, Inc. Initiates 2-Year Internship Program for Area College Students Pursuing Degrees in Science (January 09, 2004)

Memphis, Tenn., January 09, 2004 - GTx, Inc., a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily for serious men's health conditions and diseases, announced today the initiation of a 2-year Internship Program targeting local collegiates pursuing careers in the fields of Science and Science Technology. As the Company continues to recruit local and international talent to support its research and development, GTx is interested in supplementing its staff with future catalysts in the field of biotechnology.

The program is designed to provide positive, meaningful work experiences for a select number of college students for up to two years. At the onset of the program, GTx will primarily target second - or third-year college students equipped to apply the skills and knowledge they have acquired thus far. Additionally, GTx will be recruiting outstanding graduating high school students who are capable of challenging research outside academia. Mitchell S. Steiner, M.D., founder and CEO of GTx commented, "GTx believes in supporting and drawing from local talent to help further establish Memphis as a premier player in the biotechnology field."

About GTx, Inc. GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions and diseases. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has two product candidates that are in human clinical trials. The company is developing Acapodene™, its most advanced product candidate, through clinical trials for two separate indications: (1) a Phase IIb clinical trial for the reduction in the incidence of prostate cancer in men with precancerous prostate lesions and (2) the pivotal Phase III clinical trial for the treatment of serious side effects of advanced prostate cancer therapy. GTx is initially developing its second product candidate, Andarine, for the treatment of cachexia, or muscle wasting, that occurs in various types of cancer.